CCM

Concord Medical Services Holdings Limited (CCM) Economic Moat Analysis (2026)

Invetso Score: 2.7/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.8 (Weak)

CCM does not appear to rely on proprietary brands, patents, or regulated IP that would let it sustain pricing power versus peers, so any differentiation is likely replicable.

The absence of disclosed long-run margin or ROIC evidence in the provided metrics weakens the case that intangible assets are translating into durable peer outperformance.

Compared with stronger-moat peers that can defend price through recognized IP or entrenched brands, CCM looks more exposed to commodity-like competition and customer price sensitivity.

No filing-based evidence provided here indicates exclusive licenses, regulatory barriers, or other protected assets that would materially improve retention over a 5–10 year horizon.

Switching Costs

Score:

The negative TTM ROIC and ROCE suggest CCM is not currently monetizing customer lock-in in a way that would support durable switching costs versus peers.

The very low asset turnover implies limited evidence of a high-friction, embedded workflow advantage that would make customers materially dependent on CCM.

Compared with peers that benefit from software integration, compliance dependence, or mission-critical installed bases, CCM appears to have weaker retention leverage.

No Tier 1 evidence was provided showing contractual lock-in, proprietary data migration costs, or operational disruption that would raise switching costs over time.

Network Effects

Score:

There is no evidence in the provided materials that CCM benefits from a self-reinforcing user, data, or marketplace network that compounds value versus peers.

Negative profitability metrics argue against a network-driven flywheel that would be converting scale into stronger pricing power or lower churn.

Compared with platform peers where more users directly improve product utility, CCM does not show signs of ecosystem dependence or peer-recognized network advantage.

No filing evidence was provided for two-sided participation, data network effects, or partner ecosystems that would make the moat structurally durable.

Cost Advantage

Score:

CCM’s negative ROIC and ROCE indicate it is not currently demonstrating a cost structure advantage that would let it underprice peers while preserving returns.

The low asset turnover suggests capital intensity or underutilized assets, which usually weakens rather than strengthens unit-cost competitiveness versus peers.

Compared with peers that can leverage scale procurement, automation, or superior logistics to sustain margins, CCM does not show clear evidence of a durable cost edge.

No filing-based evidence was provided for structurally lower input costs, advantaged sourcing, or process efficiency that would persist across a 5–10 year period.

Efficient Scale

Score:

The provided metrics do not indicate that CCM operates in a niche where market size naturally supports one or a few efficient incumbents with durable pricing power.

Negative returns and weak asset efficiency suggest CCM is not capturing the kind of scale economics that would deter peer entry or expansion.

Compared with peers in highly concentrated markets, CCM does not show evidence of regulatory, capacity, or geographic constraints that would preserve an efficient-scale moat.

No Tier 1 evidence was provided that CCM controls a limited market, critical infrastructure, or scarce distribution that would make competition structurally uneconomic.

Overall Score

Score:

CCM’s moat appears weak versus peers because the provided metrics show negative capital returns and limited asset efficiency, while there is no evidence of protected intangibles, meaningful switching costs, network effects, cost advantage, or efficient-scale dynamics that would sustain pricing power or retention over 5–10 years.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Concord Medical Services Holdings Limited. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →